Myriad Genetics Acquires Precise Tumor, Precise Liquid And Laboratory From Intermountain Precision Genomics; Deal Terms Not Disclosed

Author: Benzinga Newsdesk | January 19, 2024 02:28am

"With this acquisition, we're deepening our commitment to our oncology business while also generating a more effective way to scale and grow our tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities," said Paul J. Diaz, president and CEO, Myriad Genetics. "We'd like to thank our longstanding partners at Intermountain Healthcare for the important progress they've made in advancing precision oncology care. We look forward to continuing to build on this foundation to provide comprehensive genomic profiling options to the Intermountain Health System and its patients and providers that can help guide clinical care and improve patient outcomes."

Posted In: MYGN